Calreticulin 3 Protein (CALR3)

Catalog No. ABIN7318227

This Recombinant Calreticulin 3 protein is expressed in Escherichia coli (E. coli).

Quick Overview for Calreticulin 3 Protein (CALR3) (ABIN7318227)

Target: Calreticulin 3 (CALR3)

Protein Type: Recombinant

Origin: Human

Source: Escherichia coli (E. coli)

Purity: > 95 % as determined by reducing SDS-PAGE.

Product Details

Purpose: Recombinant Human Calreticulin-3/CALR3 Protein

Sequence: Thr 20-Leu384

Characteristics: Recombinant Human calreticulin-3 is produced by our E.coli expression system and the target gene encoding Thr20-Leu384 is expressed.

Sterility: 0.2 μm filtered

Endotoxin Level: < 1.0 EU per μg of the protein as determined by the LAL method.

Biological Activity Comment: Not validated for activity

Application Details

Restrictions: For Research Use only

Handling

Format: Lyophilized

Buffer: Lyophilized from a 0.2 μm filtered solution of 20 mM Tris-HCl, 150 mM NaCl, 5 % Trehalose, 5 % Mannitol, 0.02 % Tween 80, 1 mM EDTA, pH 8.0.
Normally 5 % - 8 % trehalose, mannitol and 0.01 % Tween 80 are added as protectants before lyophilization.

Storage: 4 °C,-20 °C,-80 °C

Storage Comment: Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80°C. Reconstituted protein solution can be stored at 4-8°C for 2-7 days. Aliquots of reconstituted samples are stable at < -20°C for 3 months.

Expiry Date: 12 months

Target Details

Target: Calreticulin 3 (CALR3)

Alternative Name: Calreticulin-3/CALR3

Background: CALR3,CRT2,Calreticulin-3,calreticulin-2,calsperin,Calreticulin-3 belongs to the calreticulin family, members of which are calcium binding chaperones localized mainly in the endoplasmic reticulum. It can be divided into a N-terminal globular domain, a proline-rich P-domain forming an elongated arm-like structure and a C-terminal acidic domain. During spermatogenesis process, Calreticulin-3 may act as a lectin-independent chaperone for specific client proteins such as ADAM3. Defects in CALR3 are the cause of familial hypertrophic cardiomyopathy type 19 (CMH19), it is a hereditary heart disorder characterized by ventricular hypertrophy, which is usually asymmetric and often involves the interventricular septum. The symptoms include dyspnea, syncope, collapse, palpitations, and chest pain.

Molecular Weight:

Calculated MW: 42.9 kDa

Observed MW: 40-50 kDa

Gene ID: 125972

UniProt: Q96L12

Pathways: Activation of Innate immune Response